Close Menu

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with cancer drug developer FLX Bio to create a novel RNA-based immuno-oncology (IO) analysis platform.

According to Cofactor, the platform — called Cofactor Paragon — will be developed using its Sigmund RNA signature analysis technology and RNA assay development expertise, along with FLX Bio's purified immune cells, validation samples, and tumor samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Jun
26
Sponsored by
Lexogen

This webinar will outline a study that combined genome-wide and classical molecular approaches to demonstrate that translation strongly affects mRNA stability in a codon-dependent manner, ultimately influencing mRNA and protein levels in higher organisms.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.